Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NYS: PBYI) , a development stage biopharmaceutical company, announced the initiation of its Phase III clinical trial of the Company's lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior treatments (third-line disease).
The Phase III trial will be a randomized trial of PB272 plus Xeloda versus Tykerb plus Xeloda in patients with third-line HER2-positive metastatic breast cancer. The trial is expected to enroll approximately 600 patients who will be randomized (1:1) to receive either PB272 plus Xeloda or Tykerb plus Xeloda. The trial will be conducted at approximately 150 sites in North America, Europe and Asia-Pacific. The co-primary endpoints of the trial are progression free survival and overall survival. The Company plans to use the progression free survival data from the trial, which is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration, as the basis for submission of a New Drug Application (NDA) to the FDA for accelerated approval of PB272 for this indication. The Company also plans to use the progression free survival data from this trial to support a Market Authorization Application (MAA) to the European Medicines Agency for conditional approval for PB272 in the same indication.
Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, "Commencing the Phase III trial of PB272 in HER2-positive metastatic breast cancer represents an important milestone in the global development of PB272 and for Puma as a company. We look forward to aggressively enrolling this trial and to pursuing additional registration opportunities for PB272 in HER2-positive breast cancer and in tumors with a mutation in the HER2 kinase, including non-small cell lung cancer, breast cancer and the other solid tumors that we will be studying in our upcoming basket trial."
About Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (neratinib), an oral potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer and non-small cell lung cancer.
Further information about Puma Biotechnology can be found at www.pumabiotechnology.com.
This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing; the Company's dependence on its lead drug candidate, which is still under development and may never receive regulatory approval; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Company's drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Company's products; the Company's reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; the Company's dependence on licensed intellectual property; and the other risk factors disclosed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2013. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.
Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian
Andreas Marathovouniotis or David Schull
KEYWORDS: United States North America California
The article Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.